Clinical Trials Logo

Metastatic Gastric Cancer clinical trials

View clinical trials related to Metastatic Gastric Cancer.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05703555 Withdrawn - Clinical trials for Metastatic Breast Cancer

INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701

INTRUSION
Start date: February 16, 2024
Phase: Phase 2
Study type: Interventional

This study is a prospective, open-label, multi-cohort, exploratory phase II clinical trial in patients with either CEACAM5-positive NSQ NSCLC, ER+ breast cancer or gastric cancer. Eligible subjects will receive Tusamitamab ravtansine (100mg/m2 IV Q2W). The investigators hypothesize that intratumoral exposure of Tusamitamab ravtansine would be an important factor in determining treatment efficacy. Combining exposure with measurements of tumor PD reactions in a proper PK/PD study is the goal of this study.